PSI Sci
New here? Follow the money and the votes · Not sure of your district? Find your U.S. House member · Find your state legislators

H.R. 2427: Pharmaceutical Market Access Act of 2003

Before you vote › Federal bills

H.R. 2427: Pharmaceutical Market Access Act of 2003

108th Congress · introduced 2003-06-11 · Health · Latest: Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

federal

Follow this bill, step by step

  1. Where it came from: introduced 2003-06-11 · official record
  2. Who proposed it: Rep. Gutknecht, Gil [R-MN-1] · what a sponsor is
  3. What happened next: 1 recorded vote in our records. Latest: House roll call 445 (2003): On Passage, HR2427 (2003-07-25), Passed. See all
  4. Where it stands now: Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions. Not final yet: this can still change. We check for updates every day.
  5. If it becomes law and spends money: follow the money to money laws, then agencies and contracts and grants.

What does this mean?

Official title

Pharmaceutical Market Access Act of 2003

Plain summary

(This measure has not been amended since it was introduced. The summary has been expanded because action occurred on the measure.) Pharmaceutical Market Access Act of 2003 - (Sec. 4) Amends the Federal Food, Drug and Cosmetic Act to direct the Secretary of Health and Human Services to promulgate regulations allowing qualifying individuals to import covered products (in addition to pharmacists and wholesalers, whom current law authorizes to import such products). Amends provision pertaining to record keeping regarding imported covered products. States that the Secretary shall not have to store records in cases in which qualifying individuals have imported a covered product. Amends provisions regarding the importation of covered products, including to remove language directing the Secretary to require that a foreign seller specify the original source of the product and the amount of each lot of the product originally received. Amends provisions regarding the testing of imported covered products. Declares that specified tests, including ones involving authenticity and degradation of products, shall not be required unless the importer is a wholesaler. Requires such tests to be conducted by the importer unless a product is a prescription drug subject to the provisions of this Act pertaining to counterfeit-resistant packaging. (Currently either the importer or the manufacturer may conduct such tests). Eliminates the sunset date current law establishes for the provisions pertaining to the importation of covered products. (Sec. 5) Classifies prescription drugs as misbranded if they do not incorporate specified counterfeit-resistant technologies in packaging.

Congressional Research Service summary (Passed House without amendment), quoted unchanged (nonpartisan). Read the source.

What a vote does

A “Yea” vote

If it passes both chambers and is signed, it becomes law.

A “Nay” vote

If it is not passed, current law stays as it is.

PSI Sci description of the legislative step (not an opinion).

What does this mean? (plain words)

Official text

Pharmaceutical Market Access Act of 2003

Source: Congressional Research Service summary (Passed House without amendment)

AI explanation – may be wrong, check the official text

No AI explanation yet. It takes up to a minute to write and is then saved for everyone.

Limited to a few requests an hour per person.

The strongest published arguments

Arguments for (supporters)

Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.

Arguments against (opponents)

Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.

Alternatives

Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.

How did my representative vote? · This bill's floor votes

Officials and money

Sponsor: Rep. Gutknecht, Gil [R-MN-1] · 53 cosponsors

Cost estimate: CBO cost estimate: H.R. 2427, Pharmaceutical Market Access Act of 2003 (2003-11-19); CBO cost estimate: H.R. 2427, Pharmaceutical Market Access Act of 2003 (2003-11-19)

Cosponsors on this site

Michael K. Simpson (R-ID), Rosa L. DeLauro (D-CT), Chris Van Hollen (D-MD), Christopher H. Smith (R-NJ), Bernard Sanders (I-VT), John B. Larson (D-CT)

Recorded votes

Words on this page, explained (1)
Rulemaking
The process agencies use to write regulations that carry out laws passed by Congress or a legislature. Usually an agency publishes a proposed rule, takes public comments, then publishes a final rule.

Plain meanings written from linked sources. All words.

Sources

Record fed-us-cong108-hr2427 · catalog fed-us-congress-bills-cong108 · updated 2026-11-15 by psicol fed-bills-cong108